Rbf Capital, LLC Kezar Life Sciences, Inc. Transaction History

Rbf Capital, LLC

$1.71 Billion
Q2 2024

A detailed history of Rbf Capital, LLC transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Rbf Capital, LLC holds 282,521 shares of KZR stock, worth $152,561. This represents 0.01% of its overall portfolio holdings.

Number of Shares

282,521

Holding current value

$152,561

% of portfolio

0.01%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.6 - $0.92 $169,512 - $259,919	282,521 New	282,521 $169,000
Q2 2021 Aug 16, 2021	SELL	$4.93 - $6.46 $59,899 - $78,489	-12,150 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$5.24 - $6.99 $214,840 - $286,590	-41,000 Reduced 77.14%	12,150 $72,000
Q3 2020 Nov 16, 2020	BUY	$4.36 - $5.5 $166,334 - $209,825	38,150 Added 254.33%	53,150 $257,000
Q3 2020 Nov 16, 2020	SELL	$4.36 - $5.5 $166,334 - $209,825	-38,150 Reduced 71.78%	15,000 $1.2 Million
Q1 2020 May 18, 2020	SELL	$2.77 - $5.75 $100,551 - $208,725	-36,300 Reduced 40.58%	53,150 $232,000
Q4 2019 Feb 13, 2020	BUY	$2.5 - $4.26 $223,625 - $381,057	89,450 New	89,450 $359,000

Others Institutions Holding KZR

# of Institutions

Shares Held

39.6M

Call Options Held

3.2K

Put Options Held

700

Suvretta Capital Management, LLC New York, NY

7.17M
Shares

$3.87 Million
0.18% of portfolio
Avidity Partners Management LP Dallas, TX

5.03M
Shares

$2.71 Million
0.15% of portfolio
Vanguard Group Inc Valley Forge, PA

2.74M
Shares

$1.48 Million
0.0% of portfolio
Sphera Funds Management Ltd. Tel Aviv, L3

2.05M
Shares

$1.11 Million
0.18% of portfolio
Orbimed Advisors LLC San Diego, CA

1.93M
Shares

$1.04 Million
0.03% of portfolio

View Full List

About Kezar Life Sciences, Inc.

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $36.9M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

More about KZR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rbf Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rbf Capital, LLC with notifications on news.

Account